MedTrace Logo

Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans

NCT02539823 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-09-01

Study results available
· View outcomes & findings →

Summary

Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.

Conditions

  • Opiate Addiction

Interventions

DRUG

CBD 400 mg

Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions

DRUG

CBD 800 mg

Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions

DRUG

Control (placebo)

Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study

Sponsors & Collaborators

Principal Investigators

  • Yasmin Hurd, PhD · Mount Sinai Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-05-24
Completion
2017-05-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02539823 on ClinicalTrials.gov